rs10753123 - COP1-DT
Magnitude 2.2 · 1 study on file
Reported associations
-
Phenotype integration improves power and preserves specificity in biobank-based genetic studies of major depressive disorder - Unknown journal (n.d.) · Unknown authors · PubMed 37985818
ABSTRACT: Biobanks often contain several phenotypes relevant to diseases such as major depressive disorder (MDD), with partly distinct genetic architectures. Researchers face complex tradeoffs between shallow (large sample size, low specificity/sensitivity) and deep (small sample size, high specificity/sensitivity) phenotypes, and the optimal choices are often unclear. Here we propose to integrate these phenotypes to combine the benefits of each. We use phenotype imputation to integrate information across hundreds of MDD-relevant phenotypes, which significantly increases genome-wide association study (GWAS) power and polygenic risk score (PRS) prediction accuracy of the deepest available MDD phenotype in UK Biobank, LifetimeMDD. We demonstrate that imputation preserves specificity in its g
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
genetic risk for major depressive disorder Moderate
rs10753123 is associated with lifetime major depressive disorder per large-scale GWAS (p=3e-8, n=269,962)
discuss with healthcare provider risk stratification and preventive monitoring approach
Screening
-
mental health baseline assessment Moderate
rs10753123 carriers show elevated lifetime major depressive disorder risk via altered LINC02803 expression in substantia nigra and other brain tissues
establish baseline mental health status with validated screening tool (e.g. PHQ-9)